Home > Healthcare > Biotechnology > Biotechnology R&D > Mycoplasma Testing Market
Mycoplasma Testing Market was valued at around USD 909.5 million in 2023 and is estimated to register over 11.9% CAGR between 2024 and 2032. Mycoplasma testing involves a series of laboratory techniques designed to detect the presence of mycoplasma bacteria in various biological samples, particularly cell cultures used in research, biomanufacturing, and clinical applications. Mycoplasma is unique bacteria that lacks a cell wall, making them resistant to many antibiotics and difficult to detect using traditional staining methods.
Common testing methods include PCR, enzymatic assays, and direct culture. The increase in cell culture contamination, including mycoplasma contamination, poses significant challenges to research and biomanufacturing processes. For instance, as per estimates, over 10% of all cell cultures are believed to be tainted with mycoplasma species, underscoring the necessity of regular testing to guarantee the purity of cultures. Thus, as contamination rates rise, there's a corresponding need for robust mycoplasma testing methods to identify and mitigate contamination risks promptly.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Mycoplasma Testing Market Size in 2023: | USD 909.5 Million |
Forecast Period: | 2024 - 2032 |
Forecast Period 2024 - 2032 CAGR: | 11.9% |
2032 Value Projection: | USD 2.49 Billion |
Historical Data for: | 2018 - 2023 |
No. of Pages: | 205 |
Tables, Charts & Figures: | 348 |
Segments covered: | Product Type, Technique, Application, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Furthermore, increasing research and development activities are driving significant expansion within the mycoplasma testing market. With a rising demand for dependable and effective testing techniques such as nucleic acid tests, microbial culturing, and PCR technologies, underscores the importance of innovation in meeting evolving industry needs.